Wall Street brokerages expect MiMedx Group Inc (NASDAQ:MDXG) to announce earnings of $0.10 per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for MiMedx Group’s earnings. The lowest EPS estimate is $0.09 and the highest is $0.11. MiMedx Group reported earnings per share of $0.07 during the same quarter last year, which would indicate a positive year-over-year growth rate of 42.9%. The company is expected to issue its next earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that MiMedx Group will report full-year earnings of $0.32 per share for the current year, with EPS estimates ranging from $0.31 to $0.32. For the next financial year, analysts forecast that the firm will report earnings of $0.46 per share, with EPS estimates ranging from $0.44 to $0.47. Zacks’ EPS averages are a mean average based on a survey of analysts that follow MiMedx Group.
MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. MiMedx Group had a net margin of 11.64% and a return on equity of 17.49%. The firm had revenue of $84.60 million for the quarter, compared to the consensus estimate of $84.60 million. During the same quarter in the previous year, the firm earned $0.06 EPS. The company’s quarterly revenue was up 31.4% compared to the same quarter last year.
Shares of MiMedx Group (NASDAQ MDXG) traded down $0.08 during trading on Monday, hitting $13.86. 1,689,100 shares of the stock were exchanged, compared to its average volume of 1,980,900. The stock has a market cap of $1,540.00, a P/E ratio of 46.20, a P/E/G ratio of 1.80 and a beta of 0.88. MiMedx Group has a 52-week low of $7.64 and a 52-week high of $17.47.
MiMedx Group announced that its board has authorized a stock repurchase program on Monday, October 9th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in MiMedx Group by 0.7% during the 2nd quarter. BlackRock Inc. now owns 12,187,736 shares of the medical equipment provider’s stock worth $182,451,000 after purchasing an additional 82,382 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of MiMedx Group by 11.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,661,111 shares of the medical equipment provider’s stock valued at $84,746,000 after acquiring an additional 566,114 shares during the last quarter. State Street Corp boosted its holdings in shares of MiMedx Group by 21.9% in the 2nd quarter. State Street Corp now owns 3,960,317 shares of the medical equipment provider’s stock valued at $59,281,000 after acquiring an additional 710,515 shares during the last quarter. Atlantic Trust Group LLC boosted its holdings in shares of MiMedx Group by 2.6% in the 3rd quarter. Atlantic Trust Group LLC now owns 1,490,411 shares of the medical equipment provider’s stock valued at $17,706,000 after acquiring an additional 37,937 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of MiMedx Group by 2.2% in the 2nd quarter. Northern Trust Corp now owns 1,381,250 shares of the medical equipment provider’s stock valued at $20,677,000 after acquiring an additional 29,265 shares during the last quarter. 69.22% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/15/mimedx-group-inc-mdxg-expected-to-announce-earnings-of-0-10-per-share.html.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.